Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 8/20 | 0.54 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734178 | 0.93 | NR1I2 (0.58) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL1804942 | 0.90 | NR1I2 (0.44) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL12620172 | 0.89 | NR1I2 (0.43) | NR1I2PRKCAMMP12SCN9ACYP3A4 | |
| SCHEMBL1806121 | 0.89 | NR1I2 (0.43) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL51345 | 0.89 | NR1I2 (0.43) | NR1I2SCN9ACYP3A4CYP2C19CYP2C9 | |
| SCHEMBL13939957 | 0.88 | NR1I2 (0.56) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL1735478 | 0.88 | NR1I2 (0.56) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL13114048 | 0.87 | NR1I2 (0.56) | NR1I2PRKCAMMP12SCN9AALDH1A1 | |
| SCHEMBL13936717 | 0.87 | NR1I2 (0.50) | NR1I2PRKCAMMP12SCN9AHDAC1 | |
| SCHEMBL14004107 | 0.87 | NR1I2 (0.56) | NR1I2PRKCAMMP12SCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138171-B2 | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110020277-A1 | Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-27 | — | — | US | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-7485633-B2 | RNA polymerase, HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase inhibitor; liver disease; (+/-)-8-Cyclohexyl-N-4-(morpholinosulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)cycloprop[d]indolo[2,1-a][2]benzazepine-5-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-7399758-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-15 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | NR1I2 201/4885PRKCA 3639/4885MMP12 4396/4885 |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, OAT | NR1I2 158/4885PRKCA 2112/4885MMP12 2054/4885 |
| US-20110020277-A1 | Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors | SQLE, DHX15, FDFT1 | NR1I2 194/4885PRKCA 2671/4885MMP12 4164/4885 |
| US-20070060565-A1 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | NR1I2 201/4885PRKCA 3639/4885MMP12 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.